Literature DB >> 18474739

Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis.

Manjit Braitch1, Robert Nunan, Graham Niepel, Laura J Edwards, Cris S Constantinescu.   

Abstract

OBJECTIVE: To determine cerebrospinal fluid levels of osteopontin (OPN), a proinflammatory cytokine that was found to be overexpressed in multiple sclerosis lesions and increased in plasma during relapses and in secondary progressive multiple sclerosis.
DESIGN: Case series. Osteopontin, interleukin 12p40 (IL-12p40), IL-10, and matrix metalloproteinase 9 were measured by enzyme-linked immunosorbent assay by an investigator unaware of the patients' diagnoses. PATIENTS: Consecutive patients with multiple sclerosis (n = 27), or other inflammatory (n = 11) or non-inflammatory (n = 23) neurological diseases, undergoing lumbar puncture, were investigated.
RESULTS: Osteopontin was significantly elevated in the cerebrospinal fluid of patients with multiple sclerosis (mean [SD], 415 [186] ng/mL) and other inflammatory diseases (563 [411] ng/mL) compared with those with noninflammatory neurological diseases (286 [150] ng/mL). Cerebrospinal fluid OPN levels were slightly higher than plasma OPN levels. Cerebrospinal fluid OPN levels positively correlated with the ability to detect cerebrospinal fluid IL-12p40.
CONCLUSION: Osteopontin in the cerebrospinal fluid may be, in part, of central nervous system origin, and may play an important role in central nervous system inflammation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474739     DOI: 10.1001/archneur.65.5.633

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

Review 1.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

2.  Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice.

Authors:  Angelika Goncalves DaSilva; Lucy Liaw; V Wee Yong
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.

Authors:  John M Ringman; Howard Schulman; Chris Becker; Ted Jones; Yuchen Bai; Fred Immermann; Gregory Cole; Sophie Sokolow; Karen Gylys; Daniel H Geschwind; Jeffrey L Cummings; Hong I Wan
Journal:  Arch Neurol       Date:  2012-01

Review 4.  Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.

Authors:  Viviana Nociti; Marina Romozzi; Massimiliano Mirabella
Journal:  J Pers Med       Date:  2022-03-31

Review 5.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

6.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

7.  Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Authors:  Felicitas Strehlow; Sandra Bauer; Peter Martus; Michael Weller; Patrick Roth; Uwe Schlegel; Sabine Seidel; Carmen Scheibenbogen; Agnieszka Korfel; Stephan Kreher
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

8.  OSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM.

Authors:  Amanda Brown
Journal:  Transl Neurosci       Date:  2012-02-01       Impact factor: 1.757

9.  The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Authors:  Jürgen Glas; Julia Seiderer; Corinna Bayrle; Martin Wetzke; Christoph Fries; Cornelia Tillack; Torsten Olszak; Florian Beigel; Christian Steib; Matthias Friedrich; Julia Diegelmann; Darina Czamara; Stephan Brand
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

10.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Authors:  Serafeim Katsavos; Maria Anagnostouli
Journal:  Mult Scler Int       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.